June 1 (Reuters) - Zymeworks Inc ZYME.TO :
* CLINICAL DATA FOR ZYMEWORKS' NOVEL BISPECIFIC ANTIBODY, ZW25, PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
* ZW25 SHOWN TO BE ACTIVE AND WELL TOLERATED ACROSS A RANGE OF TUMOR TYPES
* POTENTIAL PHASE 2/3 STUDY FOR ZW25 COULD BEGIN AS EARLY AS H2 2019 PENDING DISCUSSION WITH U.S. FDA
* TREATMENT-RELATED ADVERSE EVENTS PRIMARILY GRADE 1/2, NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS/DISCONTINUATIONS SEEN FOR ZW25 IN STUDY
* STUDIES TO EVALUATE COMBINATIONS WITH ZW25 BEYOND THOSE ONGOING IN CURRENT PHASE 1 STUDY PLANNED TO START LATER THIS YEAR